Skip to main content
Shedir Pharma Group logo

Shedir Pharma Group — Investor Relations & Filings

Ticker · SHE ISIN · IT0005379620 LEI · 81560092B300849E9017 XMIL Manufacturing
Open in API
Filings indexed 124 across all filing types
Latest filing 2022-07-25 Transaction in Own Shar…
Country IT Italy
Listing XMIL SHE

About Shedir Pharma Group

https://www.shedirpharmagroup.com

Shedir Pharma Group specializes in the research, development, formulation, and commercialization of health and wellness products. The company's portfolio encompasses nutraceuticals, dermocosmetics, medical devices, and pharmaceuticals. A key focus is on innovation, resulting in the creation of unique and patented product formulations that cover approximately 15 therapeutic areas. The group operates through specialized subsidiaries that manage the entire product lifecycle, from initial research and intellectual property to marketing and distribution. Products are offered in various forms, such as capsules, tablets, powders, liquids, and gels, targeting professionals in the medical and pharmaceutical sectors.

Recent filings

Filing Released Lang Actions
AGGIORNAMENTO SULL’ESECUZIONE DEL PROGRAMMA DI ACQUISTO AZIONI PROPRIE
Transaction in Own Shares Classification · 99% confidence The document is an official communication (Informazione Regolamentata) from Shedir Pharma Group dated July 25, 2022. The subject ('Oggetto') is 'AGGIORNAMENTO SULL'ESECUZIONE DEL PROGRAMMA DI ACQUISTO AZIONI PROPRIE' (Update on the execution of the own share purchase program). The text details the number of shares bought back between July 18 and July 22, 2022, including daily aggregated and detailed transaction tables. This activity—the company buying back its own shares—directly corresponds to the definition of 'Transaction in Own Shares'. Therefore, the appropriate filing code is POS.
2022-07-25 Italian
RICAVI DALLE VENDITE IN FORTE CRESCITA +26% AL 30 GIUGNO 2022
Earnings Release Classification · 98% confidence The document is an official communication ('Informazione Regolamentata') from Shedir Pharma Group dated July 19, 2022. The subject ('Oggetto') is 'RICAVI DALLE VENDITE IN FORTE CRESCITA +26% AL 30 GIUGNO 2022' (Sales Revenue in Strong Growth +26% as of June 30, 2022). It presents preliminary consolidated revenue figures for the first half of 2022 (H1 2022). This content aligns perfectly with an Earnings Release (ER), which is the initial announcement of periodical financial results, highlighting key figures before the full formal report (which is scheduled for September 29, 2022). It is not the comprehensive Interim Report (IR) itself, but the preliminary announcement. Key indicators: 1. Period: First semester 2022 (H1 2022). 2. Content: Key financial highlights (revenue growth). 3. Future Action: Full results to be approved by the Board on September 29, 2022, confirming this is a preliminary release. H1 2022
2022-07-19 Italian
AGGIORNAMENTO SULL’ESECUZIONE DEL PROGRAMMA DI ACQUISTO AZIONI PROPRIE
Transaction in Own Shares Classification · 98% confidence The document is an official communication from Shedir Pharma Group S.p.A. regarding the execution of its share buyback program ('AGGIORNAMENTO SULL'ESECUZIONE DEL PROGRAMMA DI ACQUISTO AZIONI PROPRIE'). It details the number of shares purchased, the period (July 11 to July 15, 2022), and the transaction details. This activity—the company buying back its own shares—directly corresponds to the definition of 'Transaction in Own Shares'. The filing code for this is POS.
2022-07-18 Italian
AGGIORNAMENTO SULL’ESECUZIONE DEL PROGRAMMA DI ACQUISTO AZIONI PROPRIE
Transaction in Own Shares Classification · 100% confidence The document is an official communication from Shedir Pharma Group S.p.A. titled "AGGIORNAMENTO SULL'ESECUZIONE DEL PROGRAMMA DI ACQUISTO AZIONI PROPRIE" (Update on the execution of the own share purchase program). It details the number of shares bought back between July 4th and July 8th, 2022, including transaction details and total value. This activity—the company buying back its own shares—directly corresponds to the definition of 'Transaction in Own Shares'. The filing code for this is POS.
2022-07-11 Italian
BREVETTO NAXX® CONCESSO NEGLI STATI UNITI
Regulatory Filings Classification · 95% confidence The document is titled 'BREVETTO NAXX® CONCESSO NEGLI STATI UNITI' (NAXX® PATENT GRANTED IN THE UNITED STATES) and is explicitly labeled as a 'COMUNICATO STAMPA' (PRESS RELEASE). It announces a specific corporate event: the granting of a US patent for a composition related to respiratory tract disorders. The metadata shows it was received on July 11, 2022, and the content is short, focusing on the announcement itself rather than being a comprehensive report (like a 10-K or IR). This structure—a brief announcement about a specific, non-financial corporate event (patent grant)—fits best under the general 'Regulatory Filings' category (RNS) as it is a mandatory disclosure, although it is not a standard SEC form. Given the options, RNS serves as the best fit for a general regulatory announcement that isn't a standard financial report, management change, or dividend notice. It is not an Earnings Release (ER) or a Capital/Financing Update (CAP).
2022-07-11 Italian
Avvio del programma di acquisto di azioni proprie
Transaction in Own Shares Classification · 98% confidence The document is an official communication from Shedir Pharma Group S.p.A. titled 'Avvio del programma di acquisto di azioni proprie' (Start of the own share purchase program). This directly relates to the company buying back its own shares, which falls under the definition of 'Transaction in Own Shares'. The document details the authorization, purpose, and mechanics of the share repurchase program. This aligns perfectly with the 'Transaction in Own Shares' category (POS). It is not a full annual report (10-K), an earnings release (ER), or a general regulatory filing (RNS), as it concerns a specific corporate action related to capital management.
2022-06-17 Italian

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.